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SUMMARY
Cytomegalovirus (CMV) is the leading cause of congenital infection and non-genetic
sensorineural hearing loss in children. There are no recent data on the incidence of CMV
infection during pregnancy in Canada. This present study was undertaken to determine the
seroprevalence of CMV IgG antibodies and the rate of seroconversion in a cohort of pregnant
women in the province of Québec, Canada. We used serum samples and questionnaire data
collected as part of the 3D Pregnancy and Birth Cohort Study (2010–2013) conducted in Québec,
Canada. CMV IgG antibodies were determined in serum samples collected at the first and third
trimesters. Associations between independent variables and seroprevalence were assessed using
logistic regression, and associations with seroconversions, by Poisson regression. Of 1938
pregnant women tested, 40·4% were seropositive for CMV at baseline. Previous CMV infection
was associated with: working as a daycare educator, lower education, lower income, having had
children, first language other than French or English, and being born outside Canada or the
United States. Of the 1122 initially seronegative women, 24 (2·1%) seroconverted between their
first and third trimesters. The seroconversion rate was 1·4 [95% confidence interval (CI) 0·9–2·1]/
10 000 person-days at risk or 3·9 (95% CI 2·5–5·9)/100 pregnancies (assuming a 280-day
gestation). The high proportion of pregnant women susceptible to CMV infection (nearly 60%)
and the subsequent rate of seroconversion are of concern.
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INTRODUCTION
Cytomegalovirus (CMV) is a common congenital in-
fection. Reported birth prevalence rates range from
0·18% to 2·0% in Western Europe and from 0·44%
to 6·2% in the United States [1]. The only published
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Canadian study, conducted in Hamilton, Ontario, be-
tween 1973 and 1976, reported a birth prevalence of
0·42% [2].
Congenital CMV infection (cCMV) leads to long-
term sequelae including sensorineural hearing loss
and cognitive and motor deficits. Based on data
pooled from 15 studies from Western Europe, USA,
Canada and Japan, it was estimated that 13% of chil-
dren with cCMV infection will present specific symp-
toms at birth and, of these, 40–48% will have
permanent sequelae. Of children with asymptomatic
cCMV infection, it was estimated that 13·5% will de-
velop long-term sequelae [3].
Cumulative evidence to date suggests that primary
CMV maternal infection during pregnancy will result
in a transmission of the virus to the fetus in 40% of
cases, whereas 1% of women who are already infected
before pregnancy (known CMV IgG+) will transmit
the virus, either through reactivation or re-infection
[1]. The risk of transmission from mother to child
seems to increase throughout the stages of pregnancy
[4] but, when the fetus is infected earlier in gestation,
there is an increased risk of sequelae [5, 6]. When
fetal infection is the result of maternal primary infec-
tion, the clinical outcome for the infant (and later, the
child) is, in general, poorer than when it is the result of
reactivation or re-infection (i.e. when the mother is al-
ready CMV IgG+) [1, 7].
CMV is shed in urine and saliva, and transmission
occurs through contact with these fluids [8]. It can also
be acquired sexually [9]. Risk factors associated with
CMV infection include having young children, espe-
cially if they are attending daycare [10] and working
in contact with young children in a non-hospital set-
ting (e.g. daycare) [8, 11].
There are no population-level data on the sero-
prevalence of CMV IgG antibodies in the Canadian
population. A survey of 206 daycare educators in
Toronto, Ontario (97% females) found seroprevalence
rates of 56% in those aged <30 years and 65% in those
aged 530 years [12]. In 2001, a survey of female day-
care educators in Montréal, Québec obtained sero-
prevalence rates of 45%, 57% and 67% in those aged
20–29, 30–39 and 40–49 years, respectively [13]. The
US National Health and Nutrition Examination
Survey III (NHANES III, 1988–1994) reported sero-
prevalence rates of 47·3%, 54·4%, 59·7% and 69·8%
in females aged 12–19, 20–29, 30–39 and 40–49
years, respectively [14]. Similarly, there are no recent,
representative data on the incidence of CMV infection
in pregnant women or on the birth prevalence of
cCMV infection. Of 56 initially seronegative daycare
providers (i.e. a known high-risk population) from
Toronto, Ontario, seven (12·5%) seroconverted over
a follow-up period of ∼1 year [12].
The present study was undertaken to determine the
seroprevalence of CMV IgG antibodies and the rate of
seroconversion in a cohort of pregnant women in the
province of Québec, Canada.
MATERIALS AND METHODS
Study population
The study population originated from the 3D
(Découvrir, Développer, Devenir) Cohort Study [15].
This is a prospective study of 2366 pregnant women
followed in eight healthcare centres in three cities in
southern Québec, enrolled mostly during their first tri-
mester of pregnancy. The cohort was assembled to
study the effect of a range of factors on pregnancy
and birth outcomes. A questionnaire documenting
sociodemographic information, and medical and ob-
stetric history was administered to the women, and
serum samples were collected at up to four time points
during pregnancy (i.e. during the first, second, and
third trimesters, and at delivery). For the samples
used in this study, first trimester samples had been col-
lected between May 2010 and August 2012, and third
trimester/delivery samples had been collected between
October 2010 and February 2013.
Serological tests
Semi-quantitative determination of CMV IgG anti-
bodies by ELISA was done using Captia CMV IgG
kits (Trinity Biotech, USA) analysed on a Triturus
automated system (Grifols). All sera were analysed
using kits from the same batch. Women with equivo-
cal results at their first trimester were included in the
calculation of baseline seroprevalence rate but
excluded from the follow-up.
Statistical analyses
Data were analysed using SAS software v. 5.1 (SAS
Institute, USA). Seroprevalence rates were determined
as the number of participants positive for CMV IgG
in all those with a valid test result (negative, equivocal
or positive). Associations between independent vari-
ables and CMV IgG seroprevalence were determined
by simple and multiple logistic regressions, and odds
ratios (ORs) and 95% confidence intervals (CIs)
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were calculated. The seroconversion rate was calcu-
lated as an incidence rate using, as the denominator,
the number of person-days at risk (i.e. the sum of
the number of days between the first and last sero-
logical tests). The 95% CI of the seroconversion rate
was calculated by Ulm’s exact method based on the
relation between Poisson and χ2 distributions [16].
Associations between independent variables and
CMV seroconversion were determined by Poisson
regressions, and relative risks and 95% CIs were calcu-
lated. Missing values for independent variables were
considered as a separate category for logistic and
Poisson regression analyses, so all records were
included in all analyses.
Ethics
The 3D Cohort Study had been initially approved by
the Research Ethics Board of the Centre de recherche
du Centre hospitalier universitaire Sainte-Justine. The
consent form in the 3D study allowed for the subse-
quent use of data and biobanked serum in other stud-
ies such as the current study. The current study was
approved by the Research Ethics Board of the
Centre de recherche du Centre hospitalier universitaire
Sainte-Justine and by that of Health Canada.
RESULTS
A total of 1938 pregnant women from the original 3D
cohort had serum samples available from both their
first trimester of pregnancy and from their third tri-
mester or delivery, and were therefore included in
this study. Their characteristics are described in
Table 1. Of these, 40·4% were seropositive for CMV
IgG antibodies based on their first trimester test result.
Age 535 years, being single or divorced, working
as a daycare educator or as an orderly, having second-
ary education or less, lower household income, having
had children (excluding the current pregnancy), first
language other than English or French, and being
born outside Canada or the United States were asso-
ciated with a higher risk of being seropositive. Of
these factors, all but age, marital status and working
as an orderly showed independent associations with
seropositivity in multiple logistic regressions (Table 2).
When the analysis was restricted to mothers born
in Canada or the United States, results were similar
except that there was no association at all between
age and seropositivity in simple logistic regression
(Table 3).
A total of 1122 participants initially seronegative
had either their third trimester (n = 1106) or delivery
serum sample (n= 16) tested. Time intervals between
the collection of first trimester and third trimester/de-
livery samples ranged from 106 to 224 days (mean 148
days). Twenty-four of these women seroconverted (i.e.
2·1%). This yielded a seroconversion rate of 1·4 (95%
Table 1. Characteristics of study participants from the
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Single or divorced 101 5·2









Secondary not completed 42 2·2
Secondary completed 149 7·7
Post-secondary 525 27·1
University 1206 62·2
Household income, Canadian dollars
0–29 999 193 10·0
30 000–59 999 364 18·8
60 000–99 999 705 36·4














Mexico and Central/South America 105 5·4
Numbers do not add up to 1938 (i.e. number of pregnant
women included in this study) because of missing values
for some variables.
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CI 0·9–2·1)/10 000 person-days at risk, or 3·9 (95% CI
2·5–5·9)/100 pregnancies (assuming a standard gesta-
tion period of 40 weeks or 280 days), or 5·1% (95%
CI 3·2–7·7) on an annual basis. None of the partici-
pants’ characteristics documented in the study showed
a significant association with seroconversion, al-
though a marginal increase in risk (P = 0·0748) was
observed in women born outside Canada or the
USA (Table 4).
DISCUSSION
This is the largest study of CMV infection in a preg-
nant population in Canada. Moreover, with strict
definitions of positive and negative such as those
used in this study, and exclusion of equivocal results
in the seroconversion calculations, our seroconversion
rates are solid and reliable.
In this study, a large proportion (58%) of women
was seronegative for CMV during the first trimester
of pregnancy, placing them at risk for primary CMV
infection. Three-quarters of women born in Canada
and the United States were susceptible to primary
CMV infection compared to one quarter of those
born outside of these countries. This significant differ-
ence between the two groups of women (OR 8·65 of
being positive for CMV IgG if born outside Canada
or USA) remained strong after adjustment for
Table 2. Cytomegalovirus IgG seroprevalence from the 3D Pregnancy and Birth Cohort Study, Québec, 2010–2013
N n % Unadjusted OR (95% CI) Adjusted OR (95% CI)
Age, years
17–29 763 283 37·09 Reference Reference
30–34 758 303 39·97 1·13 (0·92–1·39) 1·03 (0·79–1·32)
35–47 412 195 47·33 1·51 (1·20–1·94) 0·94 (0·68–1·29)
Marital status
Married or common law 1835 728 39·67 Reference Reference
Single or divorced 101 54 53·47 1·75 (1·169–2·61) 1·61 (0·99–2·62)
Occupation
Nurse or midwife 166 58 34·94 0·81 (0·58–1·14) 0·85 (0·57–1·28)
Orderly 36 26 72·22 3·94 (1·89–8·22) 1·65 (0·68–4·00)
Daycare 23 17 73·91 4·29 (1·68–10·94) 4·49 (1·57–12·82)
Other or unknown 1713 681 39·75 Reference Reference
Education
Primary or secondary 191 109 57·07 2·04 (1·50–2·78) 1·97 (1·34–2·92)
Post-secondary 525 194 36·95 0·90 (0·73–1·11) 0·94 (0·72–1·24)
University 1206 476 39·47 Reference Reference
No data 16 3 18·75 0·35 (0·10–1·25) 0·34 (0·07–1·55)
Household income, Canadian dollars
0–59 999 557 326 58·53 3·79 (2·96–4·86) 1·53 (1·10–2·12)
60 000–99 999 705 243 34·47 1·41 (1·11–1·79) 1·11 (0·84–1·46)
5100 000 586 159 27·13 Reference Reference
No data 90 54 60·00 1·44 (0·81–2·55)
Number of babies ever born*
0 1075 390 36·28 Reference Reference
51 863 392 45·42 1·46 (1·22–1·76) 1·36 (1·09–1·70)
Number of children still alive*
0 1089 399 36·64 Reference
51 849 383 45·11 1·42 (1·18–1·71)
First language
French or English 1435 383 26·69 Reference Reference
Other 501 399 79·64 10·75 (8·39–13·75) 3·84 (2·76–5·34)
Country of birth
Canada or USA 1315 324 24·64 Reference Reference
Other 620 458 73·87 8·65 (6·95–10·76) 3·67 (2·70–4·98)
OR, Odds ratio; CI, confidence interval; N, Number of women in category; n, number of seropositive women.
* Excluding the current pregnancy
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confounders (OR 3·65). The higher CMV seropreva-
lence observed in mothers born outside Canada is
consistent with previous Canadian studies [12, 13].
Several risk factors for higher seroprevalence were
found to be consistent with those previously published.
CMV seropositivity was significantly more frequent in
mothers who had more children [12, 13] and in those
with lower socioeconomic status, as expressed by in-
come and education indicators [17, 18].
Working with young children, outside of healthcare
settings, is recognized as a high-risk occupation for
CMV infection. Indeed, in a study carried out in
Toronto, Canada, in the 1990s, an annual seroconver-
sion rate of 12·5% was observed in daycare educators
[12]. We did observe a higher CMV seropositivity in
daycare workers. In Quebec, under the province’s
preventive withdrawal/reassignment programme for
pregnant and breast-feeding women, pregnant work-
ers whose occupation (such as daycare educators) con-
stitutes a hazard to their health or to the health of
their fetus may request to be reassigned or, if this
not feasible, to be withdrawn from the workplace
[19]. In this study, the small number of initially sero-
negative daycare educators (n= 6) precluded any fur-
ther analysis in this group.
In contrast with previous research, age presented a
more complex picture. In univariate analysis, sero-
prevalence increased with age, which is consistent
with findings from NHANES in the United States
[14] but this effect was lost in the multivariate analysis.
When age was included in a regression model with
other variables such as country of origin, it became
Table 3. Cytomegalovirus IgG seroprevalence in women born in Canada or USA from the 3D Pregnancy and Birth
Cohort Study, Québec, 2010–2013
N n % Unadjusted OR (95% CI) Adjusted OR (95% CI)
Age, years
17–29 581 144 24·8 Reference
30–34 507 125 24·7 0·99 (0·75–1·31)
35–47 225 55 24·4 0·98 (0·69–1·40)
Marital status
Married or common law 1245 296 23·8 Reference Reference
Single or divorced 70 28 40·0 2·14 (1·30–3·51) 1·67 (0·95–2·93)
Occupation
Nurse or midwife 116 20 17·2 0·63 (0·381–1·04) 0·71 (0·43–1·19)
Orderly 12 4 33·3 1·51 (0·45–5·05) 1·08 (0·30–3·89)
Daycare 14 8 57·1 4·02 (1·38–11·69) 3·96 (1·31–11·97)
Other or unknown 1173 292 24·9 Reference Reference
Education
Primary or secondary 137 61 44·5 2·82 (1·93–4·11) 1·91 (1·24–2·95)
Post-secondary 397 91 22·9 1·04 (0·78–1·39) 0·89 (0·65–1·23)
University 771 171 22·2 Reference Reference
No data 10 1 10·0 0·39 (0·05–3·10) 0·34 (0·04–2·77)
Household income, Canadian dollars
0–59 999 275 94 34·2 2·00 (1·43–2·78) 1·46 (0·97–2·19)
60 000–99 999 516 116 22·5 1·11 (0·82–1·51) 1·12 (0·81–1·53)
5100 000 489 101 20·7 Reference Reference
No data 35 13 37·1
Number of babies ever born*
0 747 153 20·5 Reference Reference
51 568 171 30·1 1·67 (1·30–2·15) 1·64 (1·26–2·13)
Number of children still alive*
0 756 157 20·8 Reference
51 559 167 29·9 1·63 (1·26–2·09)
First language
French or English 1263 299 23·7 Reference Reference
Other 52 25 48·1 2·99 (1·71–5·22) 2·68 (1·50–4·79)
OR, Odds ratio; CI, confidence interval; N, Number of women in category; n, number of seropositive women.
* Excluding the current pregnancy.
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less important as a determinant of infection, and when
the seroprevalence data were analysed separately in
Canada/United States-born women, the seropreva-
lence did not vary by age group, even in univariate
analysis. The lack of increase in seroprevalence with
age in this cohort may be explained by the fact that
most infection is acquired in infancy and childhood,
with a subsequent more gradual increase during adult-
hood. In the study of daycare workers cited above [13],
all study subjects were at increased risk relative to the
population as a whole and the age range was wider.
The rate of seroconversion observed in this study
[3·9/100 pregnancies (assuming a standard gestation
period of 40 weeks or 280 days) or 5·1% on an annual
basis] is in the upper range of rates previously
observed in pregnant women in the United States
and higher than most rates reported from Europe
[20]. This relatively high rate of seroconversion during
pregnancy in a group of adult women with low rates
of seropositivity (40%) raises questions about the
source of infection in this population and why these
women have not seroconverted before. Although we
could not answer these important questions with our
study, we propose a few hypotheses.
First, there have been major changes in the sociode-
mographic landscape of the province of Québec over
the last 50 years that have likely influenced the epidemi-
ology of CMV. Up until 1950, Québec’s birth rate was
very high at >30 births/1000. It then plummeted to ∼10
births/1000 in 2000 [21, 22]. There was a major influx of
women in the workforce, gradually increasing from
1970 onwards [23]. In 1997, the provincial government
Table 4. Cytomegalovirus seroconversions in participants from the 3D Pregnancy and Birth Cohort Study, Québec,
2010–2013
No. of
seroconversions Rate* Unadjusted RR (95% CI) P
Age, years
17–29 12 1·74 1·29 (0·54–3·06) 0·5620
30–34 9 1·35 Reference
35–47 3 0·99 0·73 (0·20–2·70) 0·6398
Marital status
Married or common law 23 1·44 Reference
Single or divorced 1 1·52 1·06 (0·14–7·82) 0·9571
Education
Primary or secondary 1 0·88 0·72 (0·09–5·47) 0·7466
Post-secondary 9 1·90 1·55 (0·66–3·63) 0·3117
University 13 1·23 Reference
No data 1 5·16 4·21 (0·55–32·17) 0·1661
Household income, Canadian dollars
0–59 999 5 1·54 0·88 (0·83–2·53) 0·8116
60 000–99 999 7 1·06 0·61 (0·23–1·56) 0·2996
5100 000 11 1·75 Reference
No data 1 1·99 1·14 (0·15–8·84) 0·8993
Number of babies ever born†
0 12 1·22 Reference
51 12 1·77 1·46 (0·65–3·24) 0·3581
Number of children still alive†
0 12 1·21 Reference
51 12 1·79 1·48 (0·67–3·30) 0·3347
First language
French or English 20 1·30 Reference
Other 4 3·13 2·41 (0·82–7·04) 0·1091
Country of birth
Canada or USA 18 1·24 Reference
Other 6 2·87 2·32 (0·92–5·84) 0·0748
RR, Relative risk; CI, confidence interval;
* Rate/10 000 person-days at risk.
†Excluding the current pregnancy.
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started an ambitious subsidized daycare programme
and that markedly changed the way children were
cared for during working hours. Since then, at least
75% of Québec children now attend daycare (either in
a daycare facility or in a home-based daycare) before
they enter school [24]. There are, therefore, many
CMV-seronegative women (60% of our cohort) at
risk of exposure to CMV during their second preg-
nancy. We were unable to assess if there was an
increased rate of seroconversion in women who had al-
ready had children and who might have attended day-
care (and therefore be at higher risk of transmission)
because this information was not part of the 3D
study questionnaire. In another study in Québec,
Canada, among women who had had older children,
82% of these children had been in daycare [25].
Second, there was a trend towards more seroconver-
sion, although not reaching statistical significance, in
those seronegative women who were born outside
Canada or the United States. This suggests that living
in an environment with higher CMV viral burdens
(76% of that group was seropositive) may be a risk
factor for acquiring CMV. The small number of
CMV seroconversions limited our ability to investi-
gate risk factors associated with them.
It is also possible that, in a diverse population of
pregnant women, the acquisition of CMV is from so
many different types of exposures that no single specific
risk can be identified. Some probably acquire the virus
through their children, some from a work exposure,
and some through their sexual partner. It is disappoint-
ing not to be able to clearly identify risk factors.
Tailoring a CMV screening programme for high-risk
pregnant women requires the identification of key risk
factors. In this large cohort, 60% of the women were
vulnerable to CMV primary infection. Periodically fol-
lowing the CMV status of all these seronegative women
during pregnancy does not seem like a feasible option
and we did not identify a group of women suitable
for targeted screening based on risk factors for serocon-
version. This leaves limited options for a preventive
strategy during pregnancy.
Educating women has been proposed as a means of
prevention of cCMV [26] but it remains an unproven
preventive strategy, as stated recently by the American
College of Obstetricians and Gynecologists [27]. In
Canada, the current guidelines of the Society of
Obstetricians and Gynaecologists of Canada on
CMV mention the need for seronegative women to
practice good hygiene [28]. Studies by Adler et al.
demonstrated that, although education of women of
childbearing age about CMV was not effective in redu-
cing rates of CMV seroconversion before pregnancy,
the education strategy was effective once the women
were pregnant [29, 30]. This suggests that motivation
to adhere to a hygiene strategy is greater once preg-
nancy is established.
This study has some limitations. First, the sociodemo-
graphic questionnaire was not designed to specifically
assess risk factors associated with CMV seroconversion
or seropositivity. By the time we developed our study,
the enrolment in the 3D study had been completed
and sociodemographic data had been collected.
However, several participants’ characteristics documen-
ted in the 3D study were identified as risk factors for
CMV infection (e.g. occupation, socioeconomic status,
number of children). Still, more details on CMV knowl-
edge, hand-washing and child-rearing practices would
have been useful.
Findings from this study may not be generalizable
to the entire Québec population because participants
were recruited among pregnant women planning to
deliver in eight large university hospitals, of which
six are in Montréal (the largest city of the province)
and the remaining two in two smaller, but still
large cities (Québec City and Sherbrooke). These
women may be different from those from smaller cit-
ies and rural or remote areas with respect to various
sociodemographic characteristics found in this study
to be associated with CMV infection, such as educa-
tion, income, and country of origin. Indeed, the
percentage of university graduates among study par-
ticipants (62%) was much higher than that measured
in new mothers in recent a population-based survey
(35%) [31].
Finally, the main limitation is that we were not able
to ascertain if vertical transmission of CMV had actu-
ally occurred. The babies born in the 3D study did not
have urine or saliva stored that we could have used for
CMV testing. We know that 24 women experienced
seroconversion. In theory, these are primary infections
and we should expect 40% transmission to the fetus:
meaning nearly 10 cCMV-infected infants.
In conclusion, our study showed that a significant
proportion of women are seronegative for CMV and
are at risk of acquiring the infection during preg-
nancy. Furthermore, nearly 4% of these susceptible
women seroconverted in the course of a 280-day
pregnancy. This highlights a potential important hid-
den health issue for children. Further research is
needed to ascertain the burden of cCMV infection
in the population.
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